Polypeptides, cells, and methods involving engineered CD16

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10464989
APP PUB NO 20170174743A1
SERIAL NO

15300024

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

This disclosure describes, generally, a modified form of CD 16, genetically-modified cells that express the modified CD 16, and methods that involve the genetically-modified cells. The modified form of CD 16 can exhibit increased anti-tumor and/or anti- viral activity due, at least in part, to reduced susceptibility to ADAM17-mediated shedding upon NK cell stimulation.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • REGENTS OF THE UNIVERSITY OF MINNESOTA

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Jing, Yawu Shoreview, US 3 13
Kaufman, Dan Samuel Woodbury, US 6 14
Ni, Zhenya Edina, US 3 12
Walcheck, Bruce Kenneth Lino Lakes, US 5 13
Wu, Jianming Plymouth, US 234 2148

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 May 5, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 5, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00